X
Xu‐Chao Zhang
H指数:49
被引数:9,024
浏览量:0
个人简介
暂无内容
教育背景
暂无内容
工作经历
暂无内容
荣誉奖项
暂无内容
Fenestrating Adenocarcinoma A Novel Salivary Gland Cancer With EWSR1::BEND2 Fusion and Predilection for the Pharynx
筛状腺癌:一种具有EWSR1::BEND2融合基因且好发于咽部的唾液腺癌新类型
High specific capacity O3-NaNi₁/₃Fe₁/₃Mn₁/₃O₂ cathode material for sodium-ion batteries
高比容量O3-NaNi₁/₃Fe₁/₃Mn₁/₃O₂正极材料用于钠离子电池
Solid State Ionics
IF3.3
Distinct Role of TP53 Co-mutations in Different EGFR Subtypes Mediating the Response to EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
TP53共突变在不同EGFR亚型中调节非小细胞肺癌对EGFR酪氨酸激酶抑制剂反应的特异作用
Clinical Lung Cancer
IF3.3
PEARL: A Multicenter Phase 2 Study of Lorlatinib in Patients with ALK-Rearranged NSCLC and Central Nervous System Disease
PEARL:一项关于洛拉替尼在ALK重排非小细胞肺癌合并中枢神经系统疾病患者中的多中心II期研究
Clinical Lung Cancer
IF3.3
Redoxhigh phenotype mediated by KEAP1/STK11/SMARCA4/NRF2 mutations diminishes tissue-resident memory CD8+T cells and attenuates the efficacy of immunotherapy in lung adenocarcinoma
KEAP1/STK11/SMARCA4/NRF2突变介导的Redoxhigh表型减少了组织驻留的记忆性CD8 T细胞并减弱了肺腺癌的免疫治疗效果
ONCOIMMUNOLOGY
IF6.3
PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, randomized, controlled trial
未经治疗的晚期非小细胞肺癌患者sintilimab与pembrolizumab联合或不联合铂类双重化疗的PD-L1表达指南 (CTONG1901): 一项2期随机对照试验
SCIENCE BULLETIN
IF21.1

